固体脂质微囊矩阵的优化,以提高猪中L-lysine的释放和生物可用性
Costanza Bonnici1, Maria Federica Marchesi1, Martina Felici2
1Dipartimento di Scienze Mediche Veterinarie (DIMEVET), Università di Bologna, via Tolara di Sopra 50, Ozzano dell'Emilia, 40064 Bologna, Italy.
Animals : an open access journal from MDPI
|June 26, 2025
概括
优化固体脂质微囊 (SLMs) 在猪中改善了L-lysine (L-Lys) 的吸收. 这些SLMs增强了胃保留和控制释放,提高了L-Lys生物可用性,以改善猪的营养.
科学领域:
- 动物营养 动物营养
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
背景情况:
- L-lysine (L-Lys) 对于猪的生长至关重要,但由于肠道吸收有限,其生物利用性较差.
- 目前的L-Lys补充剂面临着胃分解和快速肠道过渡的挑战,阻碍有效利用.
研究的目的:
- 通过优化固体脂质微囊 (SLMs) 来增强胃留,控制肠道释放,并改善L-Lys的全身可用性.
- 评估L-Lys装载的SLMs在体外和体内性能,以改善猪的营养.
主要方法:
- 使用化甘油三甲酸 (C16:0或C18:1) 或自由脂肪酸,以不同的乳化剂度制定SLM.
- 试验室评估涉及模拟的胃 (素缓冲,pH 5.0) 和肠道 (胰腺缓冲,pH 6.5) 条件,以评估保留和释放.
- 在体内对断奶猪进行的研究比较了口服盐水,自由L-Lys和L-Lys SLMs,并在24小时内监测血L-Lys水平.
主要成果:
- 与自由脂肪酸 (48%) 相比,基于化甘油三的SLMs表现出优异的胃保留 (94-95%).
- 优化的SLMs (C16:0甘油三,1%乳化剂) 实现了90%的肠道释放,明显高于非优化的配方.
- 在体内,L-Lys SLMs延迟了血L-Lys峰值 (Tmax为3-4小时而不是1小时),并在24小时内增加了血L-Lys总量,这表明生物可用性得到改善.
结论:
- 优化的SLM有效地增强L-Lys的胃保留和控制肠道释放,从而改善了猪的全身可用性.
- 固体脂质微封装是一种有前途的策略,可以克服L-Lys补充剂在动物营养中的生物可用性限制.
相关概念视频
Bioavailability Enhancement: Drug Solubility Enhancement
499
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
499
Bioavailability Enhancement: Drug Permeability Enhancement
352
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
352
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Modified-Release Drug Delivery Systems: Bioavailability
170
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
170


